BRIEF published on 04/03/2024 at 17:17, 7 months 20 days ago Travis Perkins Announces Director/PDMR Shareholding Activities Market Abuse Regulation PDMR Shareholding Travis Perkins Stock Transaction
PRESS RELEASE published on 04/03/2024 at 17:12, 7 months 20 days ago Travis Perkins: Director/PDMR Shareholding Travis Perkins plc announced exercise and sale of shares by Director/PDMR to meet tax liabilities and transfer of shares to Director's spouse in accordance with Market Abuse Regulation Market Abuse Regulation Shareholding Travis Perkins Plc Exercise Of Options Director/PDMR
BRIEF published on 03/27/2024 at 08:05, 7 months 28 days ago Travis Perkins Announces CEO Nick Roberts to Step Down Shareholder Value Travis Perkins Leadership Change CEO Resignation Company Modernization
PRESS RELEASE published on 03/27/2024 at 08:00, 7 months 28 days ago Travis Perkins: Directorate Change Travis Perkins plc announces Nick Roberts stepping down as CEO after 5 years. Nominations Committee searching for successor. Focus on profitability and efficiency Efficiency CEO Nick Roberts Travis Perkins Plc Nominations Committee
BRIEF published on 03/22/2024 at 08:34, 8 months 2 days ago Travis Perkins Announces Date for 2024 Annual General Meeting Annual General Meeting Shareholders Financial Reporting Travis Perkins 2024 Notice
PRESS RELEASE published on 03/22/2024 at 08:29, 8 months 2 days ago Travis Perkins: Publication of the 2024 Notice of Annual General Meeting Travis Perkins plc announces the 2024 Notice of Annual General Meeting on 22 April 2024 at Linklaters, London. Shareholders can access the notice on the company's website Annual General Meeting Shareholders Travis Perkins Plc 2024 Notice Of AGM Linklaters London
BRIEF published on 03/12/2024 at 16:57, 8 months 11 days ago Travis Perkins Announces Director's Share Purchase Under BAYE Scheme PDMR Share Purchase Travis Perkins BAYE Scheme Market Regulation
PRESS RELEASE published on 03/12/2024 at 16:52, 8 months 11 days ago Travis Perkins: Director/PDMR Shareholding Travis Perkins (TPK) Director/PDMR, Nick Roberts, purchased 21 ordinary shares on 11th March 2024 under the BAYE scheme. Notification made according to UK Market Abuse Regulation PDMR Shareholding UK Market Abuse Regulation Travis Perkins Director
BRIEF published on 03/12/2024 at 14:33, 8 months 11 days ago Travis Perkins Announces Publication of 2023 Annual Report and Accounts Financial Performance 2023 Transparency Annual Report Travis Perkins
PRESS RELEASE published on 03/12/2024 at 14:28, 8 months 11 days ago Travis Perkins: Publication of the Annual Report and Accounts 2023 Travis Perkins plc announces the publication of its Annual Report and Accounts 2023, available for download in pdf format on their website Financial Results Investors Annual Report Travis Perkins Plc Accounts 2023
Published on 11/22/2024 at 23:55, 1 day 11 hours ago Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 1 day 12 hours ago Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 1 day 12 hours ago Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 1 day 13 hours ago Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.
Published on 11/22/2024 at 18:14, 1 day 17 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 17:53, 1 day 17 hours ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 1 day 18 hours ago EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/21/2024 at 06:58, 3 days 4 hours ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 3 days 16 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 3 days 17 hours ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 3 days 17 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
